Hyderabad combines a dense pharmaceutical and contract-research base with a fast-growing population of global capability centres serving multinational parents. India's Digital Personal Data Protection Act 2023 sets the local data baseline and the CDSCO regulates drug and device approvals, but the binding constraint for most GCC work is the parent regime: the system must satisfy the headquarters' EU AI Act, FDA or equivalent standard. A partner who can build to the stricter parent standard while honouring DPDP and CDSCO avoids the rework that comes from designing to the local floor.
Hyderabad is one of India's largest pharma and life-sciences clusters and a major home for global capability centres. Moweb delivers fixed-fee, in India Standard Time, shipping to production in 8 to 16 weeks with an audit pack mapped to the DPDP Act 2023, the EU AI Act and ISO 42001 so the work meets the global parent's regime.
We build to the stricter of the two, which for most Hyderabad GCCs is the parent's regime. If headquarters operates under the EU AI Act or FDA expectations, the system is designed to clear that bar, and the audit pack shows compliance with both the parent standard and India's DPDP Act so neither side has to compromise.
We design to the Digital Personal Data Protection Act 2023's consent, notice and data-fiduciary duties, with particular care for the health data common in pharma and CRO work. The audit pack records lawful basis and data flows so your data-protection lead can account for the system as the rules and rules-of-implementation settle.
Where a system influences a regulated product or clinical decision, we treat CDSCO's expectations, and the parent market's device regime, as design inputs: validation evidence, change control and traceability are built in. We are explicit about where a use case crosses into regulated software so your regulatory team engages early, not after the build.